February 07, 2024, Mumbai – Sanjivani Paranteral Limited (BSE: 531569), a pharmaceutical company, specializing in the manufacturing and distribution of high-quality parenteral and oral solid products, announced its unaudited financial results for the quarter and nine months ended 31st December 2023.
Key financial highlights for Q3FY24:
- Revenue from operations grew by 64% YoY to Rs 14.96 crore as compared to Rs 9.12 crore in Q3FY23 driven by venturing the new geographies and better utilisation of the manufacturing capacities.
- Profit after tax (PAT) increased by 73% to Rs 1.65 crore from Rs 95 Lac in Q3FY23 on account of higher sales.
Commenting on the Q3FY24 performance, Mr. Ashwani Khemka, Managing Director, Sanjivani Paranteral Limited. said, “We witnessed significant growth in our performance this quarter; revenue from operations grew by 64%. The notable uptick in sales, revenue, and net income underscores our company’s resilience and strategic acumen. As we move forward, we remain focused on driving sustainable growth and delivering strong returns for our shareholders.”